BOLT - Bolt Biotherapeutics, Inc. Total Debt to Capital

Bolt Biotherapeutics relies on patent protection for its developments in targeted tumor therapy, receiving support from specialized investment funds. In US laboratories, Bolt Biotherapeutics creates innovative drugs based on the Boltbody system to stimulate the immune response. The recruitment of leading immunologists and scientists through stock option programs complements the share price visualized below, where the debt-to-equity ratio stands at 1.70.

For Bolt Biotherapeutics (BOLT), the financial risk indicator (debt-to-equity) reflects balance sheet resilience during a period of strict resource optimization and refocusing on its priority oncology drug. This metric is calculated as the ratio of total liabilities to equity, measuring the business's degree of dependence on external borrowings, which allows investors to assess bankruptcy risk in the event of a liquidity shortage.